In this study, we prospectively analyzed the tumor BRCA1/2 status in FFPE samples from 223 patients with EOC, aiming (i) to ascertain the feasibility of the tumor NGS-based BRCA test in the clinical setting, and (ii) to evaluate the prevalence of tumor BRCA1 and BRCA2 mutations in a single-institution cohort of women with epithelial ovarian cancers. This evidence concerns the gene BRCA1 and ovarian carcinoma.